INVEST IN REFLEX TODAY!

The Five-Second Neurological Vital

Bringing innovation to the digital medical device market, Reflex Pro is a neurological testing and clinical support tool for medical practitioners working with concussion patients and more. Since launching Reflex in 2019, the company has experienced at least 180% growth from 2019 to 2022 and is seeking funding to scale in step with customer demand. Our team has developed what we believe is the most powerful pupillometer technology on the market – able to measure the eye’s reaction to light and provide neurological results using a mobile app in seconds. Reflex is a Class I 510(k) Exempt medical device under 21 CFR 886.1700 and should only be used by licensed medical professionals.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Reflex

$83,899.46 Raised

REASONS TO INVEST

Reasons Icon

The patented proprietary tech behind Reflex Pro is what’s known as Software as a Medical Device (SaaMD, the company also has a standing license for all of its direct competitor's pupillometer patents). What makes the tool unique is that it doesn’t require any peripheral hardware to obtain valuable neurological vital metrics. ​​Medical personnel can download the software, create an account, and administer testing quickly, using only their smartphone.

Reasons Icon

Reflex and the company’s associated services will leverage momentum and a growing marketplace. Currently the digital health sector is expected to reach $551B by 2027, with a double-digit CAGR of 16.5%.* We are also providing a new rapid scale solution within the market for neurological biomarkers, which was valued at over $6B in 2020, and growing at a rate of 12.9%.*

Reasons Icon

In just a few short years, the Reflex team has quickly established viability, growing the company’s gross revenue by 180+% annually. A major third-party publication with a population over 20,000 proves Reflex as a biomarker of concussion, while also obtaining third-party validation in clinical studies backed by the National Institutes of Health* and the Department of Defense.*

*Market information provided by (source) (source) (source) (source)

overview


Leveraging Machine Learning and Mobile Tech to Support The Clinical Diagnostic Process


Offering cutting-edge patented technology in an accessible and cost-effective format, Reflex’s testing suite can be used to easily capture neurological vitals. This is critical to diagnosing concussions and a multitude of other medical conditions. Reflex Pro works by integrating with mobile phone or tablet processors to measure the pupillary light reflex and provide actionable metrics that support the diagnostic process. To the best of our knowledge, Reflex Pro is the only clinically validated tool of its kind, collecting anonymized data en masse for a common database, and using it to continually optimize product capabilities.

the problem & our solution


Providing Real-Time Diagnostic Data for Modern Medical Professionals



Within the medical community, functional neurologists are collectively tasked with 71M patient visits each year – encompassing a $360B industry – but they are largely operating without access to objective neurological vitals (source). These clinicians are often the first to diagnose and treat concussions among other neurological disorders, but the lack of rapid testing and quantitative data makes it difficult to give patients accurate assessments of their injury and recovery status. 



To solve this systemic need, Reflex has developed a patented 5-second neurological vital testing suite that allows practitioners to instantly access meaningful neurological metrics. Reflex Pro is easy to implement within any medical practice via a simple tiered subscription model for unlimited testing. In independent clinical studies our system has been proven effective as a biomarker of concussion (source), scoring higher than all other adjacent technologies evaluated (source). Meanwhile, additional research demonstrates that it may be a valuable asset in other diagnostic capacities, such as assessing opiate withdrawal, autism, and Parkinson's.

the market & our traction 


A Proven Business Model Supported By Sound Concussion Science 


According to a recent FDA survey, the average cost to bring a middle-regulated, pre-revenue product to market is $31M (source), yet the Reflex team has been able to build, launch, and scale Reflex through its early adoption phase, as a medical device, with a starting investment of just over $900K.  



Milestones reached within our first two years as a company includes over 210 clinics and 30K patients served, with a customer retention rate of 96% and 90% gross revenue growth in 2021. The company has been able to secure patent protection for its ability to carry out testing on all mobile devices. Additionally, our company has a standing license for all of our direct competitor's pupillometer patents. Reflex's model includes proprietary machine learning technology for efficient, low-error processing.



Most excitingly, Reflex Pro has achieved proof-positive status through third-party clinical studies. The technology was featured in the largest neuro-pupillometric study ever conducted in 2021, with a patient population of over 20K (source), and was selected for a Department of Defense study in a 2-year concussion management study after receiving the institution's highest evaluation score (source).

why invest


Enlightening Medical Professionals On a Global Scale 




For centuries, doctors have understood the connection between the pupils and neurological health (source), yet it’s taken hundreds of years for innovation to catch up and provide the proper support tools. Having developed a tech-enhanced solution that we hope will serve over 5 million physicians, nurses, athletic trainers, physical therapists, and chiropractors worldwide, Reflex is seeking to lead the way and ready to embark on our path to expansion. Our ten-year vision entails scaling our sales and staff, finalizing Class II clinical clearance with an indication for concussion, and positioning the technology as an industry standard. Help us realize our mission by investing today!


Code View
Code View
Choose Link

ABOUT

HEADQUARTERS

1230 Hoyt Ave
Indianapolis, IN 46032
VALUATION

$15.48M

Bringing innovation to the digital medical device market, Reflex Pro is a neurological testing and clinical support tool for medical practitioners working with concussion patients and more. Since launching Reflex in 2019, the company has experienced at least 180% growth from 2019 to 2022 and is seeking funding to scale in step with customer demand. Our team has developed what we believe is the most powerful pupillometer technology on the market – able to measure the eye’s reaction to light and provide neurological results using a mobile app in seconds. Reflex is a Class I 510(k) Exempt medical device under 21 CFR 886.1700 and should only be used by licensed medical professionals.

TEAM

Kurtis William Sluss
Kurtis William Sluss
CEO & Director

Kurtis Sluss is an engineer, inventor, and TechCrunch Disrupt Alumnus. His background is in chemical engineering and organic chemistry from Purdue University with a focus on novel drug design and disease detection methods. An interest in advanced programming and its application in medicine led him to create a novel method to detect and classify cancerous proteins through machine learning. Now, Kurtis is translating this knowledge to neuro-biomechanical evaluations using a mobile phone. He leads Brightlamp as co-Founder and CEO to maintain the vision of creating affordable diagnostic technologies on a global scale.

Michael Heims
Michael Heims
CFO & Director

Michael Heims serves as the Chief Financial Officer at brightlamp. Previously to brightlamp, Michael worked at Eli Lilly and Company as a Financial Analyst managing a budget of more than $200M. Michael left Lilly to join a role with a medium-sized private equity firm, where he grew a portfolio company from $2M in EBITDA to over $30M in less than 2 years by working as the sole acquisition advisor. While there, he contributed to a variety of aspects of due diligence of prospective companies, from quality of earnings to forecasting models, and everything in between.

TERMS

Reflex
Overview
PRICE PER SHARE
$2.37
DEADLINE
Feb 7, 2023
VALUATION
$15.48M
AMOUNT RAISED
$83,899.46
Breakdown
MIN INVESTMENT
$244.11
MAX INVESTMENT
$1,234,997.52
MIN NUMBER OF SHARES OFFERED
6,328
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
521,096

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Brightlamp, Inc.

Corporate Address

:

1230 Hoyt Ave, Indianapolis, IN 46032

Offering Minimum

:

$14,999.73

Offering Maximum

:

$1,234,997.52

Minimum Investment Amount

(per investor)

:

$244.11











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

6,329

Maximum Number of Shares Offered

:

521,096

Price per Share

:

$2.37

Pre-Money Valuation

:

$15,483,999.21











*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives & Bonuses*

Time-Based:

First 72 Hours - 15% Bonus Shares 

Next 72 Hours - 10% Bonus Shares 

Next 7 Days - 5% Bonus Shares 

Amount-Based:

$1,000 | Tier 1 

$1,000 or more and receive a year of access to Reflex Pro with Reflex Telehealth for free. This offer is only available to qualified medical professionals and validated by the Reflex Team. 

$5,000 | Tier 2

5% Bonus Shares 

$10,000 | Tier 3

10% Bonus Shares 

$20,000 | Tier 4

20% Bonus Shares

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Brightlamp, Inc. (dba "Reflex") will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.37 / share, you will receive 110 Common Stock shares, meaning you'll own 110 shares for $237. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative.

NEW UPDATES

01.27.23

Don't Sleep on This Opportunity. 10 Days to Go. 😴💤

PRESS

Article Image
TechChrunch

Brightlamp wants to use AI to spot concussions

Article Image
Healio

Smartphone app may help detect concussions

Article Image
The Medical Progress

Reflex app functions as pupillometers to detect concussion biomarkers

ALL UPDATES

01.27.23

Don't Sleep on This Opportunity. 10 Days to Go. 😴💤

01.24.23

Under 14 Days Remain: Be Part of the Next Wave in Medicine. 🌊 🏥

Help Us Help People with Neurological Challenges: Invest Today.

Our mission is bigger than just an investment. We deploy your investment specifically to help others get the neurological attention they deserve. Check it out below:



01.20.23

📢 Reflex Featured in Kaiser Health News: Check it Out!

Reflex Featured as Leader in Neurological Medical Apps

Read the rest of the article here: https://khn.org/news/article/smartphone-health-data-diagnostic-tool/

"Brightlamp’s Reflex app is a clinical decision support tool for helping manage concussions and vision rehabilitation, among other things. Using an iPad’s or iPhone’s camera, the mobile app measures how a person’s pupils react to changes in light. Through machine learning analysis, the imagery gives practitioners data points for evaluating patients. Brightlamp sells directly to health care providers and is being used in more than 230 clinics. Clinicians pay a $400 standard annual fee per account, which is currently not covered by insurance. The Department of Defense has an ongoing clinical trial using Reflex."


01.19.23

NEW: mTBI Results Confirmed for Pediatric Population w/ Reflex 💣

Discovered, Confirmed, Re-Confirmed - Reflex & mTBI

Following a seminal paper in 2021 featuring Reflex, SPARCC confirmed results in the pediatric population for mild traumatic brain injury (mTBI, otherwise known as concussion).  

01.18.23

21 Days to Go - Reflex Community Feature 👩🏻‍⚕️

01.12.23

Reflex Investor Webinar: Now On Demand

On Demand Investor Webinar Now Available

Thinking about investing in Reflex? We've got you covered with this overview webinar available on demand using this link.

Want to meet with me personally to go over the investment opportunity? You can schedule a meeting with me here.


01.10.23

Hey Watchers! We're expanding into opiate recovery. Time for a second look?

Did you add Reflex to your StartEngine watchlist? Check this article out if you're still not convinced it's time to invest. Here's the link: https://www.insideindianabusiness.com/articles/concussion-app-expands-to-opioids

01.06.23

30 Days Left, Don't Miss Out! 👋

01.05.23

Dr. Mo Mortazavi, MD is here to tell us why Reflex matters. 👀 🩺

12.30.22

Reflex Wishes You a Happy New Year 🥂

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Reflex.

$244.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$1,000.00

$1,000 | Tier 1

$1,000 or more and receive a year of access to Reflex Pro with Reflex Telehealth for free. This offer is only available to qualified medical professionals and validated by the Reflex Team.

$5,000.00

$5,000 | Tier 2

5% Bonus Shares

$10,000.00

$10,000 | Tier 3

10% Bonus Shares

$20,000.00

$20,000 | Tier 4

20% Bonus Shares

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$83,899.46
INVESTORS
39
MIN INVEST
$244.11
VALUATION
$15.48M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.